Lymphoma (follicular, rituximab-refractory) – obinutuzumab (with bendamustine) [ID841]
The National Institute for Health and Care Excellence has opened a consultation on the use of obinutuzumab for the treatment of lymphoma
Opens: 14 September 2016
Closes: 5 October 2016
To read more about this consultation, please click here.
